Given the stability over time of those mediators most closely associated with disease severity (including IL-6 and GM-CSF), we hypothesized that differences in plasma mediator levels between patients with severe and moderate COVID-19 would be apparent early in the course of disease. Here, CSF2 is linked to COVID-19.